lpa1 antagonist9 Search Results


93
MedChemExpress lpa1 antagonist9
Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. <t>LPA1,</t> 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.
Lpa1 Antagonist9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lpa1 antagonist9/product/MedChemExpress
Average 93 stars, based on 1 article reviews
lpa1 antagonist9 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.

Journal: Journal of pharmacological sciences

Article Title: A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model.

doi: 10.1016/j.jphs.2025.03.012

Figure Lengend Snippet: Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.

Article Snippet: BMS-986020, an LPA1 antagonist9 was purchased from MCE (Monmouth Junction, NJ, USA).

Techniques: Inhibition, Binding Assay, Membrane, Beta-Arrestin Assay